- Home
- ACRS vs REKR Comparison
ACRS vs REKR Comparison
Compare ACRS & REKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- REKR
- Stock Information
- Founded
- ACRS 2012
- REKR 2017
- Country
- ACRS United States
- REKR United States
- Employees
- ACRS N/A
- REKR N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- REKR Telecommunications Equipment
- Sector
- ACRS Health Care
- REKR Telecommunications
- Exchange
- ACRS Nasdaq
- REKR Nasdaq
- Market Cap
- ACRS 127.6M
- REKR 115.1M
- IPO Year
- ACRS 2015
- REKR N/A
- Fundamental
- Price
- ACRS $1.14
- REKR $0.83
- Analyst Decision
- ACRS Strong Buy
- REKR
- Analyst Count
- ACRS 7
- REKR 0
- Target Price
- ACRS $11.67
- REKR N/A
- AVG Volume (30 Days)
- ACRS 968.2K
- REKR 3.7M
- Earning Date
- ACRS 05-06-2025
- REKR 05-14-2025
- Dividend Yield
- ACRS N/A
- REKR N/A
- EPS Growth
- ACRS N/A
- REKR N/A
- EPS
- ACRS N/A
- REKR N/A
- Revenue
- ACRS $18,720,000.00
- REKR $46,028,000.00
- Revenue This Year
- ACRS N/A
- REKR $14.53
- Revenue Next Year
- ACRS $425.96
- REKR $17.91
- P/E Ratio
- ACRS N/A
- REKR N/A
- Revenue Growth
- ACRS N/A
- REKR 31.76
- 52 Week Low
- ACRS $0.95
- REKR $0.62
- 52 Week High
- ACRS $5.17
- REKR $2.67
- Technical
- Relative Strength Index (RSI)
- ACRS 27.21
- REKR 43.43
- Support Level
- ACRS $1.05
- REKR $0.73
- Resistance Level
- ACRS $1.23
- REKR $0.83
- Average True Range (ATR)
- ACRS 0.11
- REKR 0.09
- MACD
- ACRS -0.01
- REKR 0.02
- Stochastic Oscillator
- ACRS 16.82
- REKR 70.16
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About REKR Rekor Systems Inc.
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which the majority of its revenue comes from the United States.